Rapid Micro Biosystems, Inc. Class A (RPID)

In the past six months, Rapid Micro Biosystems, Inc. (RPID) stock has experienced significant fluctuations. As of April 10, 2026, the stock price was $2.12, with a 52-week range of $1.91 to $4.94. Over the last six months, the stock has fallen by approximately 40.95%. Key events include the Q4 and Full Year 2025 financial results, where the company reported record Q4 revenue but remained unprofitable. The company received a record multi-system order in Q3 2025. An analyst rating downgrade occurred in April 2026, and the company's CFO sold shares in March 2026. The company also participated in investor conferences.

Information regarding the specific demand seasonality for Rapid Micro Biosystems, Inc.'s products and services is not explicitly available. The company's focus on mission-critical quality control suggests a relatively consistent demand driven by ongoing production needs and regulatory requirements. The recurring revenue from consumables and service contracts supports a more stable demand profile.

Rapid Micro Biosystems, Inc. (RPID) is a life sciences technology company focused on automated solutions for microbial contamination detection, operating in the Pharmaceuticals & Biotech sector. Its core mission is to provide technology to biomanufacturing companies to ensure high-quality products. The company's major product is the Growth Direct® System, which automates traditional quality control microbiology testing for applications like environmental monitoring and sterility testing. The system aims to detect contamination quickly, improve QC processes, ensure data integrity, and reduce contamination risks.

Rapid Micro Biosystems is headquartered and has U.S. manufacturing in Lowell, Massachusetts, with its corporate office in Lexington, Massachusetts. Globally, it has locations in Switzerland, Germany, and the Netherlands. The company generates maximum revenue from the United States, with additional revenue from Switzerland, Germany, Japan, and other international countries.

Rapid Micro Biosystems generally maintains a reputation as a trusted partner in quality control microbiology automation. However, a news report indicated that the company faces ESG-related reputational and operational risks, which could affect its standing with investors and customers.

Rapid Micro Biosystems, Inc. (RPID) is a publicly traded company on the Nasdaq Capital Market. As of April 8, 2026, institutional investors hold 52.60% of the stock, while insiders hold 29.96%. Major institutional owners include Bain Capital Life Sciences Investors, LLC, Vanguard Group Inc, and BlackRock, Inc.